Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, November 3, 2023
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
[ Fri, Nov 03rd 2023
] - WOPRAI
Etzer Darout Maintained (CCCC) at Buy with Decreased Target to $16 on, Nov 3rd, 2023
Etzer Darout of BMO Capital, Maintained "C4 Therapeutics, Inc." (CCCC) at Buy with Decreased Target from $18 to $16 on, Nov 3rd, 2023.
Etzer has made no other calls on CCCC in the last 4 months.
There are 2 other peers that have a rating on CCCC. Out of the 2 peers that are also analyzing CCCC, 1 agrees with Etzer's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Chi Fong of "B of A Securities" Maintained at Hold with Decreased Target to $2 on, Monday, October 9th, 2023
This is the rating of the analyst that currently disagrees with Etzer
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $7 on, Thursday, November 2nd, 2023
